Diabetes

Changes in the Rap1 gene associated with leptin resistance, which promotes obesity.

Onduo use technological advances to enhance management of diabetes.

Onduo will use new technology and professional care to improve the lives of patients with diabetes.

Canagliflozin and metformin hydrochloride extended release (Invokamet) improves blood glucose control in adults with type 2 diabetes.

Canagliflozin with extended release formulation of metformin improves blood glucose control in type 2 diabetes.

The FDA has just approved Janssen's Invokamet XR, a once-daily, fixed-dose combination of canagliflozin (Invokana) and extended-release metformin hydrochloride, for first-line treatment for type 2 diabetes in adults as an adjunct to diet and exercise.

Although venomous cone snails are sea-dwelling creatures, researchers have found a remarkable use for them on land.

New strategy helps slow kidney disease progression that can occur in diabetes.

Oral administration of insulin may be possible with Cholestosomes.

The FDA has extended the regulatory review period for Novo Nordisk's IDegLira, a potential once-daily fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for adults with type 2 diabetes.

Top news of the day from across the health care landscape.

Genetically engineered mice lacking a specific protein developed diabetes at a faster rate.

Antibiotics have been found to alter gut microbiomes, which increases the risk of type 1 diabetes.

Typically used to treat type 2 diabetes, metformin could slow heart disease development in patients with type 1 diabetes.

Pharmacists are much more likely to see prescriptions for sodium-glucose co-transporter 2 (SGLT2) inhibitors than obesity medications, recent prescription data reveal.

New research compares cardiovascular issues among patients with type 2 diabetes and psoriasis.

Drugs that treat diabetes are prescribed significantly more than antiobesity medications.

Omega-3 fatty acid supplements may help address the growing prevalence of type 2 diabetes mellitus and diabetic retinopathy.

Sanofi has submitted updated information to the FDA as part of a previously submitted New Drug Application (NDA) for its investigational once-daily, fixed-ratio combination of basal insulin glargine 100 units/mL (Lantus) and lixisenatide (Adlyxin) to treat type 2 diabetes in adults.

Research advances work towards targeted therapies for type 2 diabetes.

SGLT2 inhibitors can lower blood glucose levels and potentially protect the kidneys.

Regenerative bandage could reduce amputations and poor health outcomes from diabetic sores.

One of the most frequent questions patients ask is, Can I travel with my medications?"

Flavanone consumption associated with lower levels of cell-damage markers.

Prescribed diabetes therapies may be leading to reduced kidney function.